Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14742377 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2GAAPOLBTP53ALDH1A1 | |
| SCHEMBL485162 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2GAAPOLBTP53ALDH1A1 | |
| SCHEMBL5271075 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2GAAPOLBTP53ALDH1A1 | |
| SCHEMBL3861785 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2GAAPOLBTP53ALDH1A1 | |
| SCHEMBL23937267 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2GAAPOLBTP53ALDH1A1 | |
| SCHEMBL13041496 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2GAAPOLBTP53ALDH1A1 | |
| SCHEMBL6978823 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2GAAPOLBTP53ALDH1A1 | |
| SCHEMBL30734430 | 0.79 | HRH3 (0.59) | SMN1; SMN2GAAPOLBALDH1A1TSHR | |
| SCHEMBL5010663 | 0.79 | MAPT (0.68) | GAAPOLBALDH1A1NPC1TSHR | |
| SCHEMBL716530 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2GAAPOLBTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924336-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020168143-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
| CN-105473585-B | Piperidine carboxylic acid derivative as fungicide | 拜耳作物科学股份公司 | 2018-04-13 | — | — | CN | disclosed |
| US-20170044136-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | LILLY CO ELI (US) | 2017-02-16 | — | — | US | disclosed |
| US-20150376178-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | ELI LILLY AND COMPANY | 2015-12-31 | — | — | US | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| WO-2015066515-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | RECEPTOS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8044207-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090209563-A1 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY | 2009-08-20 | — | — | US | disclosed |
| US-20080300407-A1 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (IN) | 2008-12-04 | — | — | US | disclosed |
| US-7423050-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| CN-1889951-A | Substituted benzazoles and methods of their use as inhibitors of RAF kinase | CHIRON CORP (US) | 2007-01-03 | — | — | CN | disclosed |
| EP-1492786-B1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | ELI LILLY AND COMPANY | 2005-10-06 | — | — | US | disclosed |
| EP-1492786-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084949-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | SMN1; SMN2 4772/4885GAA 4778/4885POLB 3067/4885 |
| US-20080300407-A1 | Pyridinoylpiperidines as 5-HT1F agonists | HTR1F, HTR1A, HTR1E | SMN1; SMN2 2696/4885GAA 4879/4885POLB 4473/4885 |
| US-20170044136-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | HTR1F, HTR1A, HTR1E | SMN1; SMN2 2496/4885GAA 4875/4885POLB 4463/4885 |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | HTR1F, HTR1A, HTR1E | SMN1; SMN2 2496/4885GAA 4875/4885POLB 4463/4885 |
| US-20150376178-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | HTR1F, HTR1A, HTR1E | SMN1; SMN2 2496/4885GAA 4875/4885POLB 4463/4885 |
| US-20090209563-A1 | Pyridinoylpiperidines as 5-HT1F agonists | HTR1F, HTR1A, HTR1E | SMN1; SMN2 2496/4885GAA 4875/4885POLB 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.